This study is conducted in Europe. The aim of this observational study is to evaluate glycaemic control in subjects with type 2 diabetes using once daily Levemir® as initiation of insulin therapy in Hungary.
Study Type
OBSERVATIONAL
Enrollment
1,032
Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
Novo Nordisk Investigational Site
Budapest, Hungary
Novo Nordisk Investigational Site
Budapest, Hungary
Change in HbA1c
Time frame: after 24 weeks
Percentage of subjects to reach HbA1c below 7.0% and equal to or more than 6.5%
Time frame: after 12 weeks and 24 weeks
Change in FPG (Fasting Plasma Glucose)
Time frame: after 12 weeks and 24 weeks
Change in body weight
Time frame: after 12 weeks and 24 weeks
Change in waist and hip circumference
Time frame: after 12 weeks and 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.